FrancophonIA/ELRC3.0 huggingface dataset:
English: Store the reconstituted solution for injection upright at 15 °C - 25 °C and use within 5 hours of
Slovenian: Rekonstituirano raztopino shranjujte v pokončnem položaju pri 15˚C-25˚C in jo uporabite
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Slovenian: Ime in naslov izdelovalca, odgovornega za sproščanje serij
English: WHAT NeoSpect IS AND WHAT IT IS USED FOR
Slovenian: Kaj je zdravilo NeoSpect in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo NeoSpect
English: After reconstitution with sodium pertechnetate (99mTc) solution for injection, 99mTc-depreotide is
Slovenian: Po rekonstituciji z raztopino natrijevega pertehnetata(99mTc) za injiciranje, nastane
English: The area where the radioactive compound is collected, will light up on the picture and give information on the location of the tumour.
Slovenian: Vaš zdravnik bo posnel sliko (sken) vaših pljuč z uporabo Predel v katerem se zbere radioaktivna spojina bo na sliki osvetljen in bo dal informacijo o mestu Ocena prav tako vključuje pregled s CT (slikanje z računalniško tomografijo) ali rentgensko slikanje
English: Each vial contains: 47 micrograms depreotide as depreotide trifluoroacetate
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka viala vsebuje: 47 mikrogramov depreotida v obliki depreotidnega trifluoroacetata
English: This can give the doctor valuable information such as the location of a tumour.
Slovenian: To daje lahko zdravniku dragocene
English: * flushing
Slovenian: * omotici
English: Instructions for the preparation of 99mTc-depreotide:
Slovenian: 99mTc
English: 4.2 Posology and method of administration
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
English: Reconstitute with sodium pertechnetate (99mTc) injection.
Slovenian: Rekonstituirajte z raztopino natrijevega pertehnetata (99mTc) za injiciranje.
English: The recommended dosage is one vial (approximately 47 micrograms of depreotide) labelled with
Slovenian: Priporočeno odmerjanje je ena viala (približno 47 mikrogramov depreotida) označena s 555-740 MBq
English: Date of first authorisation:19 January 2015
Slovenian: Datum prve odobritve: 19. januar 2015
English: You should not do both.
Slovenian: Obojega ne smete hkrati.
English: • are over 75 years of age
Slovenian: • če ste starejši od 75 let.
English: It is especially important to tell your doctor if you take:
Slovenian: Posebej pomembno je, da zdravniku poveste, če jemljete:
English: The clinical significance of this finding is currently unknown.
Slovenian: Klinični pomen te ugotovitve trenutno ni znan.
English: DATE OF THE REVISION OF THE TEXT
Slovenian: DATUM ZADNJE REVIZIJE BESEDILA
English: • sudden confusion, difficulty speaking,or understanding others
Slovenian: • nenadno zmedenost, težave z govorjenjem ali razumevanjem drugih
English: Your doctor will decide if this medicine is appropriate for you.
Slovenian: Zdravnik bo presodil, ali je to zdravilo primerno za vas.
English: • If you forget a dose, take it as soon as you remember.
Slovenian: • Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
English: • sudden numbness or weakness of your arm, leg or face, especially if only on one side of the body
Slovenian: • nenadno omrtvelost ali šibkost roke, noge ali obraza, zlasti, če se pojavi le na eni strani telesa
English: • double vision
Slovenian: • dvojni vid
English: The mean volume of distribution of vorapaxar is approximately 424 litres.
Slovenian: Povprečni volumen porazdelitve vorapaksarja je približno 424 litrov.
English: Treatment of presumed overdose should address signs and symptoms.
Slovenian: Zdravljenje domnevnega prevelikega odmerjanja mora biti usmerjeno na znake in simptome.
English: Patients receiving digoxin should be monitored as clinically indicated.
Slovenian: Bolnike, ki prejemajo digoksin, je treba spremljati, kot je klinično indicirano.
English: Know the medicines you take.
Slovenian: Bodite seznanjeni z zdravili, ki jih jemljete.
English: Patients with low body weight (<60 kg)
Slovenian: Bolniki z majhno telesno maso (< 60 kg)
English: • Do not take a double-dose (two doses at the same time) to make up for a forgotten dose.
Slovenian: • Ne vzemite dvojnega odmerka (dveh odmerkov hkrati), če ste pozabili vzeti prejšnji odmerek.
English: • needing an urgent operation to open blocked arteries in the heart.
Slovenian: • potrebo po nujni operaciji za odprtje zamašenih arterij v srcu.
English: Specific populations
Slovenian: Posebne populacije
English: In general, a body weight <60 kg is a risk factor for bleeding.
Slovenian: Na splošno je telesna masa < 60 kg dejavnik tveganja za krvavitve.
English: The most common adverse reaction reported during treatment is bleeding.
Slovenian: Najpogostejši neželeni učinek, o katerem so poročali med zdravljenjem, je krvavitev.
English: • sudden difficulty in walking or loss of balance or co-ordination
Slovenian: • nenadne težave s hojo ali izgubo ravnotežja ali koordinacije gibov
English: • pink, red, or brown urine
Slovenian: • rožnat, rdeč ali rjav urin
English: • bleeding that is severe or that you cannot control
Slovenian: • krvavitev, ki je huda ali je ne morete obvladati
English: The median Body Mass Index was 28.
Slovenian: Mediani indeks telesne mase je bil 28.
English: The median Body Mass Index was 27.
Slovenian: Mediani indeks telesne mase je bil 27.
English: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Slovenian: Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni je mogoče oceniti iz razpoložljivih podatkov).
English: • suddenly feeling dizzy or sudden severe headache with no known cause
Slovenian: • nenaden občutek omotice ali nenaden hud glavobol brez znanega vzroka
English: Zontivity may affect the way other medicines work, and other medicines may affect how Zontivity works.
Slovenian: Zdravilo Zontivity lahko vpliva na delovanje drugih zdravil in druga zdravila lahko vplivajo na delovanje zdravila Zontivity.
English: The safety and efficacy of Zontivity in children aged less than 18 years have not yet been established.
Slovenian: Varnost in učinkovitost zdravila Zontivity pri otrocih, mlajših od 18 let, še nista bili dokazani.
English: You may be at increased risk of bleeding.
Slovenian: Obstaja lahko večje tveganje za krvavitev.
English: There are no reliable data on the use of vorapaxar in pregnant women.
Slovenian: Zanesljivih podatkov o uporabi vorapaksarja pri nosečnicah ni.
English: Zontivity should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus.
Slovenian: Zdravilo Zontivity se sme med nosečnostjo uporabljati le, če možna korist za mater upravičuje možno tveganje za plod.
English: • Do not stop taking Zontivity without first talking to the doctor who prescribed it for you.
Slovenian: • Ne prenehajte jemati zdravila Zontivity, ne da bi se prej posvetovali z zdravnikom, ki vam ga je predpisal.
English: Zontivity is used to lower your chance of:
Slovenian: Zdravilo Zontivity se uporablja za zmanjšanje možnosti za:
English: If Zontivity must be temporarily discontinued, restart it as soon as possible.
Slovenian: Če je treba uporabo zdravila Zontivity začasno prekiniti, zdravilo čim prej znova uvedite.
English: Any unused medicinal product or material should be disposed of in accordance with local requirements.
Slovenian: Neuporabljeno zdravilo ali material zavrzite v skladu z lokalnimi predpisi.
English: These differences are not considered to be clinically relevant and no dose adjustment is necessary.
Slovenian: Te razlike ne veljajo za klinično pomembne in prilagoditev odmerka ni potrebna.
English: There is less information about other types of surgery but the overall evidence does not suggest an excessive risk of major bleeding.
Slovenian: O drugih vrstah operacij je manj informacij, toda v celoti izsledki ne kažejo povečanega tveganja za večje krvavitve.
English: Phospholipidosis occurs at acceptable human to animal safety margins and was reversible.
Slovenian: Fosfolipidoza se je pojavila ob sprejemljivi varnostni meji med človekom in živalmi in je bila reverzibilna.
English: Your doctor will determine if you should take Zontivity for more than 24 months.
Slovenian: Zdravnik bo odločil, če morate zdravilo Zontivity jemati več kot 24 mesecev.
English: The effect of vorapaxar on the QTc interval was evaluated in a thorough QT study and in other studies.
Slovenian: Vpliv vorapaksarja na interval QTc so ocenili v podrobni študiji QT in drugih študijah.
English: • Patients with any active pathological bleeding (see sections 4.4 and 4.8).
Slovenian: • bolniki s kakršno koli aktivno patološko krvavitvijo (glejte poglavji 4.4 in 4.8),
English: • red or black stools (looks like tar)
Slovenian: • rdeče ali črno blato (na pogled kot katran)
English: Keep a list of them to show your doctor and pharmacist when you get a new medicine.
Slovenian: Imejte seznam teh zdravil in ga pokažite zdravniku in farmacevtu, kadar dobite kakšno novo zdravilo.
English: Interruption of Zontivity treatment should be avoided.
Slovenian: Prekinitvi zdravljenja z zdravilom Zontivity se je treba izogibati.
English: Do not take Zontivity:
Slovenian: Ne jemljite zdravila Zontivity:
English: CYP2C8 substrates
Slovenian: Substrati CYP2C8
English: Platelet inhibition with vorapaxar is gradual and reversible.
Slovenian: Inhibicija trombocitov z vorapaksarjem je postopna in reverzibilna.
English: Table 3: CABG-Related Bleeds
Slovenian: Preglednica 3: Krvavitve, povezane s CABG
English: • have had any recent serious injury or surgery
Slovenian: • če ste pred nedavnim imeli kakšno resno poškodbo ali operacijo,
English: • if you are allergic to vorapaxar sulfate or any of the other ingredients of this medicine (listed in section 6)
Slovenian: • če ste alergični na vorapaksarjev sulfat ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
English: • Take Zontivity on a regular basis and for as long as your doctor keeps prescribing it.
Slovenian: • Zdravilo Zontivity jemljite redno in tako dolgo, dokler vam ga predpisuje zdravnik.
English: • low red blood cell count (anaemia)
Slovenian: • majhno število rdečih krvnih celic (anemija)
English: Continued therapy after this time must be based on a re-evaluation of the benefits and risks for the individual of further therapy.
Slovenian: Nadaljevanje zdravljenja po tem času mora temeljiti na ponovni oceni koristi in tveganj nadaljnega zdravljenja pri posamezniku.
English: Zontivity is used in adults who have had a heart attack or have a condition known as "peripheral arterial disease" (also known as poor circulation in the legs).
Slovenian: Zdravilo Zontivity uporabljamo pri odraslih, ki so imeli srčni infarkt ali imajo bolezen, ki jo imenujemo "periferna arterijska bolezen" (prav tako znana kot slaba prekrvavitev v nogah).
English: In these subgroups, Zontivity should only be prescribed after careful assessment of individual potential risks and benefits and the need for co-medication that may further increase the risk of bleeding.
Slovenian: Pri teh podskupinah se lahko zdravilo Zontivity predpiše le ko se pri posamezniku skrbno oceni morebitna tveganja in koristi ter potrebo po sočasnem zdravljenju, ki bi lahko dodatno povečalo tveganje za krvavitve.
English: Within that period the effect was similar regardless of the time from qualifying MI to the start of therapy with Zontivity.
Slovenian: V tem času je bil učinek podoben ne glede na čas od MI, ki je dovoljeval vključitev v študijo, do začetka zdravljenja z zdravilom Zontivity.
English: Bleeding category definitions:
Slovenian: Opredelitve kategorij krvavitev:
English: This reduces the chance of a blood clot forming and blocking the arteries, such as the arteries in the heart.
Slovenian: Tako zmanjša možnost za nastanek krvnega strdka in posledično zamašitev arterij, na primer arterij v srcu.
English: HR 95% CI p-value (Z) vs (P) 0.83 (0.76, 0.90) <.001
Slovenian: HR 95 % IZ p-vrednost (Z) vs (P) 0,83 (0,76, 0,90) < 0,001
English: • rifampin (used to treat tuberculosis and some other infections)
Slovenian: • rifampin (uporablja se za zdravljenje tuberkuloze in nekaterih drugih okužb),
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Zontivity in one or more subsets of the paediatric population in prevention of arterial thromboembolism (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Zontivity za eno ali več podskupin pediatrične populacije za preprečevanje arterijskih trombembolizmov (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Patients with events (%)
Slovenian: Bolniki z dogodki (%)
English: Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake "EXP".
English: Platelets are blood cells that help with normal blood clotting.
Slovenian: Trombociti (krvne ploščice) so celice, ki pomagajo pri normalnem strjevanju krvi.
English: This medicinal product does not require any special temperature storage conditions.
Slovenian: Za shranjevanje zdravila niso potrebna posebna navodila glede temperature.
English: Studies in rats have shown vorapaxar and/or its metabolites are excreted in milk.
Slovenian: Študije na podganah so pokazale, da se vorapaksar in/ali njegovi presnovki izločajo v mleko.
English: • have a bodyweight of less than 60 kg
Slovenian: • če imate telesno maso manjšo od 60 kg,
English: Anticoagulants
Slovenian: Antikoagulanti
English: The apparent terminal half-life for vorapaxar is 187 hours (range 115-317 hours) and is similar for the active metabolite.
Slovenian: Navidezni končni razpolovni čas vorapaksarja je 187 ur (razpon: od 115 do 317 ur) in je podoben tudi pri aktivnem presnovku.
English: Film-coated tablet 7 film-coated tablets 10 x 1 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 x 1 film-coated tablets 100 film-coated tablets
Slovenian: filmsko obložena tableta 7 filmsko obloženih tablet 10 x 1 filmsko obložena tableta 28 filmsko obloženih tablet 30 filmsko obloženih tablet 50 x 1 filmsko obložena tableta 100 filmsko obloženih tablet
English: The median duration of treatment with vorapaxar was 823 days (interquartile range: 645-1016 days).
Slovenian: Mediano trajanje zdravljenja z vorapaksarjem je znašalo 823 dni (interkvartilni razpon: 645 - 1.016 dni).
English: The recommended dose is one tablet by mouth each day taken with or without food.
Slovenian: Priporočeni odmerek je ena tableta na dan, s hrano ali brez nje.
English: There are limited data on the efficacy and safety of Zontivity beyond 24 months.
Slovenian: Podatkov o učinkovitosti in varnosti zdravila Zontivity po 24 mesecih je malo.
English: * K-M estimate at 1,080 days
Slovenian: * Ocena po K-M po 1.080 dneh.
English: Vorapaxar is also a substrate of CYP2J2; therefore, there is a potential for potent inhibitors of CYP2J2 to result in increases in vorapaxar exposure.
Slovenian: Vorapaksar je tudi substrat CYP2J2, zato obstaja možnost, da močni zaviralci CYP2J2 povečajo izpostavljenost vorapaksarju.
English: Bleeding events were treated in the same manner as for other antiplatelet agents including addressing the source of bleeding while providing supportive care.
Slovenian: Krvavitve so zdravili enako kot pri drugih antiagregacijskih zdravilih, vključno z obravnavo vira krvavitve med zagotavljanjem podporne oskrbe.
English: BE-2220 Heist-op-den-Berg Belgium
Slovenian: BE-2220 Heist-op-den-Berg Belgija
English: Pharmacokinetics of vorapaxar are similar between elderly, including those ≥75 years of age, and younger patients.
Slovenian: Farmakokinetika vorapaksarja je pri starejših bolnikih, vključno s tistimi, ki so stari ≥ 75 let, podobna kot pri mlajših.
English: Zontivity is indicated for the reduction of atherothrombotic events in adult patients with
Slovenian: Zdravilo Zontivity je indicirano za zmanjšanje aterotrombotičnih dogodkov pri odraslih bolnikih
English: Evaluation of Zontivity on QTc interval
Slovenian: Ocena vpliva zdravila Zontivity na interval QTc
English: • if you have unusual bleeding now, such as bleeding in your brain, stomach or gut
Slovenian: • če imate trenutno kakšno neobičajno krvavitev, na primer krvavitev v možganih, želodcu ali črevesju,
English: The primary route of elimination is through the faeces, with approximately 91.5% of radiolabeled dose predicted to be recovered in the faeces compared to 8.5% in the urine.
Slovenian: Glavna pot izločanja je z blatom; predvidoma se približno 91,5 % radioaktivno označenega odmerka pojavi v blatu, v primerjavi z 8,5 % v urinu.
English: However, if a patient is to undergo elective surgery, if clinically feasible, Zontivity should be discontinued at least 30 days prior to surgery.
Slovenian: Če ima bolnik predviden elektivni kirurški poseg in če je klinično izvedljivo, je treba uporabo zdravila Zontivity prekiniti vsaj 30 dni pred kirurškim posegom.
English: Age, gender, weight and race were included as factors assessed in the population pharmacokinetic model to evaluate vorapaxar pharmacokinetics in healthy subjects and patients:
Slovenian: Starost, spol, telesna masa in rasa so bili kot faktorji vključeni v populacijski farmakokinetični model za oceno farmakokinetike vorapaksarja pri zdravih osebah in pri bolnikih:
English: The systemic exposure of M20 is ~20% of the exposure to vorapaxar.
Slovenian: Sistemska izpostavljenost presnovku M20 je ~20 % izpostavljenosti vorapaksarju.
English: Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Slovenian: Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU Velika Britanija
English: What Zontivity is and what it is used for What you need to know before you take Zontivity
Slovenian: Kaj je zdravilo Zontivity in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Zontivity
English: Do not take Zontivity if any of the above apply to you.
Slovenian: Ne vzemite zdravila Zontivity, če kaj od naštetega velja za vas.
English: Among the common bleeding events, epistaxis is the most frequent.
Slovenian: Med pogostimi krvavitvami je bila najpogostejša epistaksa.
English: Vorapaxar is a weak inhibitor of the intestinal P-glycoprotein (P-gp) transporter.
Slovenian: Vorapaksar je šibek zaviralec črevesnega P-glikoproteinskega (P-gp) prenašalca.
English: Tell all of your doctors and dentists that you are taking Zontivity.
Slovenian: Vsem svojim zdravnikom in zobozdravnikom morate povedati, da jemljete zdravilo Zontivity.
English: • bleeding from cuts or wounds that is more than normal
Slovenian: • krvavitve iz ureznin ali ran, ki so močnejše kot po navadi
English: • The active substance is vorapaxar sulfate.
Slovenian: • Zdravilna učinkovina je vorapaksarjev sulfat.
English: • bleeding in your eye
Slovenian: • krvavitev v oko
English: Excipient(s) with known effect: Each film-coated tablet contains 66.12 mg of lactose (as monohydrate).
Slovenian: Pomožne snovi z znanim učinkom: Ena filmsko obložena tableta vsebuje 66,12 mg laktoze (v obliki monohidrata).
English: Patients with events*
Slovenian: Bolniki z dogodki*
English: Effects of other medicinal products on vorapaxar
Slovenian: Vpliv drugih zdravil na vorapaksar
English: Due to the unknown potential for adverse reactions in breast-feeding infants from Zontivity, discontinue breast-feeding or discontinue Zontivity; taking into account the importance of the medicinal product to the mother.
Slovenian: Zaradi neznane možnost neželenih učinkov zdravila Zontivity pri dojenih dojenčkih je treba bodisi prekiniti dojenje bodisi ukiniti zdravilo Zontivity, upoštevaje pomembnost zdravila za mater.
English: Zontivity should be initiated at least 2 weeks after a MI and preferably within the first 12 months from the acute event (see section 5.1).
Slovenian: Zdravilo Zontivity je treba uvesti vsaj 2 tedna po MI in po možnosti v prvih 12 mesecih po akutnem dogodku (glejte poglavje 5.1).
English: Vorapaxar is eliminated primarily by metabolism, with significant contribution by CYP3A.
Slovenian: Vorapaksar se izloča predvsem s presnovo, v kateri pomembno sodeluje CYP3A.
English: However, if it is within 12 hours of the next dose, skip the missed dose.
Slovenian: Če je do naslednjega odmerka manj kot 12 ur, pozabljeni odmerek izpustite.
English: Incidence (%)
Slovenian: Pojavnost (%)
English: Follow your doctor's instructions about stopping Zontivity.
Slovenian: Upoštevajte zdravnikova navodila glede prenehanja uporabe zdravila Zontivity.
English: It is not known if Zontivity will harm your unborn baby.
Slovenian: Ni znano, ali zdravilo Zontivity škoduje nerojenemu otroku.
English: Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or other surgical procedures, even if the patient does not have any signs of bleeding.
Slovenian: Na krvavitev je treba posumiti pri vsakem bolniku, ki je hipotenziven in je imel pred kratkim opravljeno koronarno angiografijo, perkutano koronarno intervencijo (PCI - percutaneous coronary intervention), obvodno operacijo koronarnih arterij (CABG - coronary artery bypass grafting) ali druge kirurške posege, tudi če bolnik nima nobenih znakov krvavitve.
English: The recommended dose of Zontivity is 2.08 mg to be taken once daily.
Slovenian: Priporočeni odmerek zdravila Zontivity je 2,08 mg enkrat na dan.
English: Bleeding time was prolonged slightly with administration of acetylsalicylic acid alone or in combination with vorapaxar.
Slovenian: Čas krvavitve se je rahlo podaljšal z uporabo acetilsalicilne kisline same ali v kombinaciji z vorapaksarjem.
English: Pre and postnatal studies in rats only showed some inconsistent developmental effects at exposures sufficiently in excess of human exposure at the RHD of 2.08 mg vorapaxar.
Slovenian: Pre- in postnatalne študije pri podganah so pokazale le nekaj nekonsistentnih razvojnih učinkov pri izpostavljenostih, ki so dovolj presegale izpostavljenost pri človeku pri RHD 2,08 mg vorapaksarja.
English: General risk of bleeding
Slovenian: Splošno tveganje za krvavitve
English: It is not known whether vorapaxar is excreted in human breast milk.
Slovenian: Ni znano, ali se vorapaksar izloča v materino mleko pri človeku.
English: Severe bleeding is uncommon, but can be life threatening.
Slovenian: Huda krvavitev se pojavi občasno, vendar je lahko življenjsko nevarna.
English: General risk factors for bleeding include older age (however, no dose adjustment is necessary in the elderly (see section 5.2)), low body weight, and reduced renal or hepatic function.
Slovenian: Splošni dejavniki tveganja za krvavitve so višja starost (vendar starejšim odmerka ni treba prilagoditi (glejte poglavje 5.2)), nizka telesna masa in zmanjšano delovanje ledvic ali jeter.
English: Patients were randomized to receive daily treatment with 2.5 mg vorapaxar sulfate (n=13,225) or placebo (n=13,224) in addition to other standard therapy.
Slovenian: Bolnike so randomizirali na vsakodnevno jemanje 2,5 mg vorapaksarjevega sulfata (n = 13.225) ali placeba (n = 13.224) poleg drugega standardnega zdravljenja.
English: Zontivity has no or negligible influence on the ability to drive and use machines.
Slovenian: Zdravilo Zontivity nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
English: Acetylsalicylic acid, vorapaxar, and clopidogrel in combination produced significant prolongation of bleeding time.
Slovenian: Acetilsalicilna kislina, vorapaksar in klopidogrel so v kombinaciji bistveno podaljšali čas krvavitve.
English: • if you have had bleeding in the brain
Slovenian: • če ste imeli krvavitev v možganih,